Browse

Efficacy of A Mouse Anti-human ICAM-1 Monoclonal Antibody, MD-3, for Kidney Transplantation in Rhesus Monkeys

Cited 0 time in Web of Science Cited 0 time in Scopus
Authors
민상일
Advisor
하종원
Major
의과대학 의학과
Issue Date
2016-02
Publisher
서울대학교 대학원
Keywords
Primate modelsMD-3Renal transplantationAcute rejectionDonor-specific antibody
Description
학위논문 (박사)-- 서울대학교 대학원 : 의과대학 의학과 외과학전공, 2016. 2. 하종원.
Abstract
Introduction: The MD-3 is a newly developed chimeric anti-human intracellular adhesion molecule 1 (ICAM-1) monoclonal antibody (mAb). The effects of this monoclonal antibody in solid organ transplantation have not been elucidated.
Methods: Five rhesus monkey renal allograft recipients treated with MD-3 induction and one recipient without MD-3 treatment were studied for the incidence of acute rejection and donor-specific antibody development. Cellular immune response was tested with ELISPOT assay. Development of anti-drug antibody was also tested. Maintenance immunosuppression included anti-CD154 mAb (hu5C8), mycophenolate mofetil and corticosteroid.
Results: No recipient monkey developed acute rejection as long as 8 months after transplantation. Donor-specific antibody was not developed in monkeys treated with MD-3. A monkey without MD-3 induction started to produce donor-specific antibody 3 weeks after cessation of anti-CD154mAb and persisted. No anti-drug antibody was detected during the study period.
Conclusions: MD-3 can be a highly promising agent for clinical use in human allotransplantation and MD-3 treatment can allow optimization of kidney transplant outcome. Further studies for refining dosages and dosing schedule of MD-3 in kidney transplantation are required.
Language
English
URI
https://hdl.handle.net/10371/122126
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Dept. of Medicine (의학과)Theses (Ph.D. / Sc.D._의학과)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse